for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

HUTCHMED (China) Ltd

HCM.L

Latest Trade

580.00GBp

Change

-44.00(-7.05%)

Volume

474,283

Today's Range

580.00

 - 

610.00

52 Week Range

337.00

 - 

656.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
624.00
Open
610.00
Volume
474,283
3M AVG Volume
3.35
Today's High
610.00
Today's Low
580.00
52 Week High
656.00
52 Week Low
337.00
Shares Out (MIL)
864.12
Market Cap (MIL)
5,011.87
Forward P/E
-10.94
Dividend (Yield %)
--

Next Event

Half Year 2021 HUTCHMED (China) Ltd Earnings Release

Latest Developments

More

Capital Group Companies Inc's Long Position In HUTCHMED Rises To 9.15% - HKEX Filing

Hutchmed (China) Marketing Authorization Application for Surufatinib Validated by EMA

The Capital Group Companies Inc Raises Stake In HUTCHMED To 8.3% - HKEX Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About HUTCHMED (China) Ltd

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Industry

Biotechnology & Drugs

Contact Info

22Nd Floor Hutchison House

10 Harcourt Road

00000

Hong Kong

+852.null.21281188

https://www.hutch-med.com/

Executive Leadership

Simon To

Executive Chairman of the Board

Christian Hogg

Chief Executive Officer, Executive Director

Chig Fung Cheng

Chief Financial Officer, Executive Director

Mark Lee

Senior Vice President - Corporate Finance & Development

May Wang

Senior Vice President - business development & strategic alliances

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.2K

2020

0.2K

2021(E)

0.3K
EPS (USD)

2018

-0.113

2019

-0.160

2020

-0.180

2021(E)

-0.785
Price To Earnings (TTM)
--
Price To Sales (TTM)
30.22
Price To Book (MRQ)
11.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.38
LT Debt To Equity (MRQ)
6.80
Return on Investment (TTM)
-26.93
Return on Equity (TTM)
-19.43

Latest News

Latest News

BRIEF-Hutchison China MediTech Announces $100 Mln Equity Investment By General Atlantic

* HUTCHISON CHINA MEDI - $100 MILLION EQUITY INVESTMENT BY GENERAL ATLANTIC

BRIEF-Hutchison China Meditech Says Fruquintinib Granted U.S. FDA Fast Track Designation

* HUTCHISON CHINA MEDITECH LTD - FRUQUINTINIB GRANTED U.S. FDA FAST TRACK DESIGNATION FOR METASTATIC COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Hutchison China MediTech To Submit NDA For Surufatinib

* HUTCHISON CHINA MEDITECH LTD - CHI-MED PLANS TO SUBMIT NDA FOR SURUFATINIB FOLLOWING PRE-NDA MEETING WITH U.S. FDA Source text for Eikon: Further company coverage:

BRIEF-Hutchison China MediTech Gets NDA Acceptance In China For Savolitinib

* HUTCHISON CHINA MEDI - NDA ACCEPTANCE IN CHINA FOR SAVOLITINIB

BRIEF-Hutchison China MediTech Says Co, Beigene Enter Into Clinical Collaboration

* CHI-MED, BEIGENE ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF SURUFATINIB, FRUQUINTINIB WITH TISLELIZUMAB

BRIEF-Hutchison China MediTech Says Surufatinib Granted USFDA Fast Track Designations

* HUTCHISON CHINA MEDI - SURUFATINIB GRANTED FDA FAST TRACK DESIGNATIONS Source text for Eikon: Further company coverage:

BRIEF-Hutchison China Meditech Says Initiated PhaseII Study Of HMPL-453

* HUTCHISON CHINA MEDITECH - INITIATED PHASE II STUDY OF HMPL-453 IN PATIENTS WITH ADVANCED MALIGNANT MESOTHELIOMA Source text for Eikon: Further company coverage:

BRIEF-Hutchison China MediTech Says Covid-19 Outbreak Posing Some Challenges To Operations In China

* COVID-19 OUTBREAK IS POSING SOME CHALLENGES TO OPERATIONS RESULTING FROM RESTRICTIONS ON MOVEMENT IN CHINA

Biotech group Chi-Med plans Hong Kong listing of up to $500 million: sources

Biotech company Hutchison China MediTech, known as Chi-Med, has filed for a Hong Kong listing, which four sources close to the matter said could raise up to $500 million.

Boost for 'made in China' medicine as Chi-Med wins key approval

Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

Boost for "made in China" medicine as Chi-Med wins key approval

Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up